人子宫内膜腺癌细胞AN3-CA

细胞名称

人子宫内膜腺癌细胞AN3-CA

货物编码

BFN60808841

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   3类

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人子宫内膜腺癌细胞AN3-CA取自55岁女性供体，该细胞源于DSMZ

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ERK genetic alteration cell panel (ATCC TCP-1033).

Part of: MD Anderson Cell Lines Project.

Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).

Doubling time: ~45-50 hours (CLS); ~55 hours (DSMZ).

Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突变

Heterozygous for MAPK3 p.Pro373Ser (c.1117C>T) (ATCC).

Heterozygous for PIK3R1 p.Arg557_Lys561delArgGluIleAspLysinsGln (c.1670_1681delGAGAAATTGACA) (ATCC).

Homozygous for PTEN p.Arg130Glnfs*4 (c.389delG) (PubMed=20944090; ATCC).

Heterozygous for TP53 p.Gly389Trp (c.1165G>T) (ATCC).

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        12,14,15 (ATCC; CLS; Cosmic-CLP; PubMed=25877200)

12,14 (DSMZ)

D3S1358        17

D5S818        11,14

D7S820        7,7.1,10 (ATCC; PubMed=25877200)

7,10 (CLS; Cosmic-CLP)

7.1,10 (DSMZ)

D8S1179        12,14

D13S317        12,14

D16S539        10,14 (ATCC; CLS; DSMZ; PubMed=25877200)

10,14,15 (Cosmic-CLP)

D18S51        15,18

D21S11        29,30

FGA        23

Penta D        9,11

Penta E        9,16

TH01        9.3,10

TPOX        8,10

vWA        14,20

参考文献

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)